Edmond J J, Greaves S C, French J K, Graham K J, Raudkivi P J, Blake J W, Gerber I L, Smith W M
Cardiology Department, Green Lane Hospital, Green Lane West, Auckland, New Zealand.
J Heart Valve Dis. 2004 May;13(3):525-8.
Thrombosis of Mosaic aortic valve bioprostheses occurring at more than one month after surgery occurs in 0.8% (95% CI 0.33-1.67%) of patients. In the two cases reported here, each patient had risk factors for thrombus formation, namely severe left ventricular impairment in one patient, while the other patient was heterozygous for prothrombin variant G20210A. The cases were treated successfully, by thrombolytic therapy with streptokinase in the first case, and by repeat aortic valve replacement in the second case. Thrombosis of bioprosthetic valves in the aortic position is rare, and a period of anticoagulation postoperatively does not invariably protect against this serious complication. In conclusion, patients with risk factors for thrombus formation should be considered for long-term anticoagulation.
人工生物瓣置换术后1个月以上发生的镶嵌式主动脉瓣生物假体血栓形成发生率为0.8%(95%可信区间0.33 - 1.67%)。在本文报告的两例病例中,每位患者均有血栓形成的危险因素,其中一例患者存在严重左心室功能不全,另一例患者为凝血酶原变异体G20210A杂合子。第一例病例通过链激酶溶栓治疗成功治愈,第二例病例通过再次主动脉瓣置换术成功治愈。主动脉瓣位生物瓣血栓形成罕见,术后抗凝一段时间并不能完全预防这一严重并发症。总之,对于有血栓形成危险因素的患者,应考虑长期抗凝治疗。